Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

Zurück zum Zitat Gaulard P, Harris NL, Pileri SA. (2017) Primary mediastinal (thymic) large B-cell lymphoma. In Swerdlow SH, Camp E, Harris NL, et al WHO classification of tumours of haematopoeitic and lymphoid tissues Revised 4th ed International Agency for Research on Cancer:314–316 Gaulard P, Harris NL, Pileri SA. (2017) Primary mediastinal (thymic) large B-cell lymphoma. In Swerdlow SH, Camp E, Harris NL, et al WHO classification of tumours of haematopoeitic and lymphoid tissues Revised 4th ed International Agency for Research on Cancer:314–316

Zurück zum Zitat Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871–3879. https://doi.org/10.1182/blood-2003-06-1841 CrossRefPubMed Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871–3879. https://​doi.​org/​10.​1182/​blood-2003-06-1841 CrossRefPubMed

Zurück zum Zitat Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277. https://doi.org/10.1182/blood-2010-05-282780 CrossRefPubMedCentralPubMed Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277. https://​doi.​org/​10.​1182/​blood-2010-05-282780 CrossRefPubMedCentralPubMed

Zurück zum Zitat Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118(10):2659–2669. https://doi.org/10.1182/blood-2011-05-326538 CrossRefPubMed Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118(10):2659–2669. https://​doi.​org/​10.​1182/​blood-2011-05-326538 CrossRefPubMed

Zurück zum Zitat Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416. https://doi.org/10.1056/NEJMoa1214561 CrossRefPubMedCentralPubMed Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416. https://​doi.​org/​10.​1056/​NEJMoa1214561 CrossRefPubMedCentralPubMed

Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group., Eastern Cooperative Oncology Group., European Mantle Cell Lymphoma Consortium., Italian Lymphoma Foundation., European Organisation for Research., Treatment of Cancer/Dutch Hemato-Oncology Group., Grupo Español de Médula Ósea., German High-Grade Lymphoma Study Group., German Hodgkin's Study Group., Japanese Lymphorra Study Group., Lymphoma Study Association., NCIC Clinical Trials Group., Nordic Lymphoma Study Group., Southwest Oncology Group., United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800 CrossRefPubMedCentralPubMed Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group., Eastern Cooperative Oncology Group., European Mantle Cell Lymphoma Consortium., Italian Lymphoma Foundation., European Organisation for Research., Treatment of Cancer/Dutch Hemato-Oncology Group., Grupo Español de Médula Ósea., German High-Grade Lymphoma Study Group., German Hodgkin's Study Group., Japanese Lymphorra Study Group., Lymphoma Study Association., NCIC Clinical Trials Group., Nordic Lymphoma Study Group., Southwest Oncology Group., United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://​doi.​org/​10.​1200/​JCO.​2013.​54.​8800 CrossRefPubMedCentralPubMed

Zurück zum Zitat Zinzani PL, Pellegrini C, Chiappella A, di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129(16):2328–2330. https://doi.org/10.1182/blood-2017-01-764258 CrossRefPubMed Zinzani PL, Pellegrini C, Chiappella A, di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129(16):2328–2330. https://​doi.​org/​10.​1182/​blood-2017-01-764258 CrossRefPubMed

Zurück zum Zitat Kim JS, Kang HJ, Dong S et al (2016) The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 128:1820 Kim JS, Kang HJ, Dong S et al (2016) The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 128:1820

Zurück zum Zitat Zinzani PL, Ribrag V, Moskiwitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130(3):267–270. https://doi.org/10.1182/blood-2016-12-758383 CrossRefPubMed Zinzani PL, Ribrag V, Moskiwitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130(3):267–270. https://​doi.​org/​10.​1182/​blood-2016-12-758383 CrossRefPubMed

Zurück zum Zitat Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068. https://doi.org/10.1038/leu.2015.212 CrossRefPubMedCentralPubMed Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068. https://​doi.​org/​10.​1038/​leu.​2015.​212 CrossRefPubMedCentralPubMed